8-K
filed September 22, 2025, 7:59 PM ET
ticker CYTK
CIK 0001061983
debt
confidence high
sentiment neutral
materiality 0.75
CYTOKINETICS INC (CYTK): debt financing — Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes
CYTOKINETICS INC
- Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.
- Used ~$402.5M cash and 2,168,806 common shares to exchange $399.5M of existing 3.50% notes due 2027.
- Initial conversion price ~$68.42 per share, ~37.5% premium over $49.76 last sale price.
- Remaining proceeds to fund aficamten commercial launch, development, pipeline, and general corporate purposes.
- Notes not redeemable before Oct 6, 2028; convertible under certain stock price and event conditions.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.98
CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.
- Instrument
- convertible notes
- Principal
- $750.0 million aggregate principal amount
- Counterparty
- initial purchasers
- Rate
- 1.75% per year
- Maturity
- October 1, 2031
- Event
- incurrence
Exact text from the filing
On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.7
CYTOKINETICS INC issued 2,168,806 shares of the common stock of common stock.
- Security
- common stock
- Shares
- 2,168,806 shares of the common stock
Exact text from the filing
The 2,168,806 shares of the common stock being issued in connection with the Note Exchange Transactions are being issued in reliance on the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CYTOKINETICS INC issued up to 15,072,300 shares of the Company's common stock of common stock.
- Security
- common stock
- Shares
- up to 15,072,300 shares of the Company's common stock
Exact text from the filing
Initially, a maximum of 15,072,300 shares of the Company's common stock may be issued upon conversion of the Notes
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CYTOKINETICS INC issued convertible note to initial purchasers for $750.0 million aggregate principal amount.
- Security
- convertible note
- Purchaser
- initial purchasers
- Consideration
- $750.0 million aggregate principal amount
Exact text from the filing
On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.